Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 6,90 € (+176,00 %). La mediana es de 6,90 € (+176,00 %).
| Comprar |
1 |
| Mantener |
0 |
| Vender |
0 |
Noticias Ir al feed de noticias
SeaStar Medical sponsors KidneyBee Summit and webinar on QUELIMMUNE for children with acute kidney failure
SeaStar Medical announces sponsorship support for the KidneyBee Summit 2026 at Children’s Hospital Colorado and a continuing-education webinar on August 11, 2026. The webinar covers the QUELIMMUNE therapy (SCD-PED) for treating critically ill children with acute kidney failure and sepsis; speakers include Dr. Stuart Goldstein, Dr. Stephen Gorga and Dr. Kevin Chung. QUELIMMUNE was approved in February 2024 via a Humanitarian Device Exemption; studies and registry data showed survival rates of about 71–77% in treated pediatric patients. The stock (NASDAQ:ICU) has risen nearly 100% year-to-date and trades at $4.79 with a market capitalization of $19.3 million. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | |
|---|---|---|
| Ingresos | 538,87 mil | 87,91 % |
| Beneficio bruto | 491,55 mil | 86,29 % |
| Beneficio neto | -3,27 M | 92,42 % |
| EBITDA | -3,25 M | 92,15 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 7,06 M € |
Número de acciones | 2,84 M |
Máximo/mínimo de 52 semanas | 10,77 € - 1,78 € |
| Dividendos | No |
Beta | -1,04 |
Ratio P/E | -0,74 |
Ratio PEG | 0,00 |
Ratio P/B | 2,74 |
Ratio P/S | 4,78 |
Perfil de la empresa
| Nombre | SeaStar Medical Holding Corp Ordinary Shares |
| CEO | Eric Schlorff |
| Empleados | 18 |
Descubrir activos
Los accionistas de SeaStar Medical Holding Corp Ordinary Shares también invierten en los siguientes activos
